Bristol Myers settles anti-generic HIV drug scheme allegations for almost $11M

Although Bristol Myers Squibb isn’t admitting to any wrongdoing, the biopharma company agreed to pay almost $11 million to settle allegations filed in a California district court that the company took part in an unlawful scheme with other pharma companies like Gilead and Janssen to protect their HIV drug profits while slowing generic competition.